Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow (MelO2)
This study is currently recruiting participants.
Verified by University Hospital, Basel, Switzerland, February 2009
First Received: May 6, 2008   Last Updated: February 19, 2009   History of Changes
Sponsored by: University Hospital, Basel, Switzerland
Information provided by: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00675181
  Purpose

Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the vasospastic syndrome (VS)?

The main questions are:

Do women with VS exhibit...

  • a different basal metabolic rate
  • a reduced choroidal blood flow
  • a reduced increase of oxygen consumption after intake of ice-water
  • a different oxygen consumption after melatonin intake
  • a different choroidal blood flow after melatonin intake
  • a different oxygen consumption after melatonin intake and after intake of ice-water….?

Condition Intervention
Vasospastic Syndrome
Healthy Subjects
Drug: Melatonin
Drug: Placebo

Study Type: Interventional
Study Design: Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Crossover Assignment
Official Title: Effects of Melatonin on Oxygen Consumption and Choroidal Blood Flow in Women With Vasospastic Syndrome in Comparison to Controls

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • -choroidal blood flow -oxygen consumption -Co2 production -skin temperatures -rectal temperatures -blood pressure -eye tension [ Time Frame: continously or 2-5 times ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: May 2008
Estimated Study Completion Date: October 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A, 1: Active Comparator
A, 1 = Melatonin
Drug: Melatonin
5mg per os
A, 2: Placebo Comparator
A,2 = Placebo
Drug: Placebo
per os

Detailed Description:

Study description:

Melatonin, a natural hormone of the pineal gland exclusively released during the dark phase, exhibits vasodilatatory effects in distal skin regions and reduces core body temperature. This study investigates whether exogenous melatonin (5mg p.o. at 2p.m.) in the afternoon, when no endogenous melatonin is secreted, increases not only distal skin blood flow, but also choroidal blood flow and changes oxygen consumption. Two subject groups were studied, women with vasospastic syndrome (VS) and controls. The main hypothesis is: melatonin normalizes distal vasoconstriction in VS.

Further questions will also be answered:

Does melatonin affect basal metabolic rate, increase choroidal blood flow and reduce the vasospastic syndrome (VS)?

Do women with VS exhibit:

  • a different basal metabolic rate
  • a reduced choroidal blood flow
  • a reduced increase of oxygen consumption after intake of ice-water
  • a different oxygen consumption after melatonin intake
  • a different choroidal blood flow after melatonin intake
  • a different oxygen consumption after melatonin intake and after intake of ice-water....?
  Eligibility

Ages Eligible for Study:   20 Years to 30 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • vasospastic syndrome
  • healthy

Exclusion Criteria:

  • sick
  • BMI >25 or <18
  • migraine
  • drug intake
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00675181

Contacts
Contact: Kurt Kraeuchi 41-61-325-5508 kurt.kraeuchi@upkbs.ch

Locations
Switzerland
University Eye Clinic Recruiting
Basel, Switzerland, 4031
Contact: Kurt Kraeuchi     41-61-325-5508     kurt.kraeuchi@upkbs.ch    
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Selim Orguel, MD University Eye Clinic, Basel, Switzerland
  More Information

No publications provided

Responsible Party: University Hospital, Basel, Switzerland ( Selim Orguel, MD )
Study ID Numbers: 087-KRK-2008-002
Study First Received: May 6, 2008
Last Updated: February 19, 2009
ClinicalTrials.gov Identifier: NCT00675181     History of Changes
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:
melatonin
skin blood flow
choroidal blood flow
vasospastic subjects
normal subjects

Study placed in the following topic categories:
Antioxidants
Central Nervous System Depressants
Melatonin
Healthy

Additional relevant MeSH terms:
Antioxidants
Pathologic Processes
Disease
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Syndrome
Physiological Effects of Drugs
Central Nervous System Depressants
Melatonin
Protective Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 02, 2009